Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated

SG&A Expenses: Teva vs. Ligand - A Decade of Change

__timestampLigand Pharmaceuticals IncorporatedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014225700005078000000
Thursday, January 1, 2015243780004717000000
Friday, January 1, 2016266210005096000000
Sunday, January 1, 2017286530004986000000
Monday, January 1, 2018377340004214000000
Tuesday, January 1, 2019418840003806000000
Wednesday, January 1, 2020644350003671000000
Friday, January 1, 2021574830003528000000
Saturday, January 1, 2022700620003445000000
Sunday, January 1, 2023527900003498000000
Monday, January 1, 20243702000000
Loading chart...

Unveiling the hidden dimensions of data

Navigating SG&A Expenses: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Over this period, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 32% from 2014 to 2023. In contrast, Ligand Pharmaceuticals experienced a significant increase of around 134% in their SG&A expenses, reflecting their strategic investments in growth and expansion.

Teva's peak SG&A expenses were recorded in 2014, while Ligand's expenses reached their zenith in 2022. This divergence highlights the distinct strategic approaches of these companies in managing operational costs. As the pharmaceutical landscape continues to shift, understanding these financial dynamics offers valuable insights into the industry's future direction.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025